


**IN THE CLAIMS**

1-10. (Cancelled)

11. (Currently Amended) Process for the preparation of the amorphous form of methyl (S)-(+)-(2-chlorophenyl)-2-(6, 7-dihydro-4*H*-thieno [3,2- c] pyridine-5-yl)-acetate hydrogen-sulfate of the formula



which comprises,

dissolving clopidogrel base in a first solvent,

adding sulfuric acid ~~or a mixture of sulfuric acid and the first solvent or a second solvent to the mixture,~~

adding the obtained mixture containing clopidogrel hydrogensulfate to ~~the~~ a second solvent to obtain a precipitate, and

filtering precipitate,

~~wherein the first solvent is selected from at least one of the group consisting of: an aprotic solvent that is less polar than the second solvent and a dipolar aprotic solvent, and~~

~~wherein the second solvent is selected from at least one of the group consisting of: an aprotic solvent, a dipolar aprotic solvent and an apolar solvent~~

wherein the first solvent and the second solvent are present in one of the following combinations selected from the group consisting of:

combination (i) acetone and diisopropyl ether;

combination (ii) dichloromethane and diisopropyl ether;

combination (iii) dichloromethane and cyclohexane; and

combination (iv) dichloromethane and ethyl acetate.

12. (Cancelled)

13. (Previously Presented) The process according to claim 11, wherein the method comprises:

dissolving clopidogrel base in dichloromethane to make a solution,  
adding sulfuric acid to the solution,  
mixing the solution with cyclohexane to form a precipitate, and  
filtering the precipitate.

14. (Previously Presented) The process according to claim 11, which further comprises:  
washing the precipitate; and  
drying the precipitate.

15-16. (Cancelled)

17. (Currently Amended) The process according to claim 11, wherein the first solvent is ~~acetone and wherein~~ and the second solvent ~~[[is]] are present in combination (i) which is acetone~~ and diisopropyl ether.

18. (Currently Amended) The process according to claim 11, wherein the first solvent is ~~dichloromethane and wherein~~ and the second solvent ~~[[is]] are present in combination (ii) which~~ is dichloromethane and diisopropyl ether.

19. (Currently Amended) The process according to claim 11, wherein the first solvent is ~~dichloromethane and wherein~~ and the second solvent ~~[[is]] are present in combination (iv) which~~ is dichloromethane and ethyl acetate.

20. (Previously Presented) The process according to claim 11, wherein said first solvent is present in an amount not greater than 37 ml per gram of clopidogrel base.

21. (Previously Presented) The process according to claim 11, wherein said first solvent is present in an amount of between 31 and 37 ml per gram of clopidogrel base.